Login / Signup

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.

Sandra Castaño-DíezHelena PomaresDaniel EstebanFrancesca GuijarroCarlos Jiménez-VicenteInés ZugastiJosé Ramón ÁlamoVíctor Torrecillas MayayoMònica López-GuerraCristina de la FuentePaola CharryAlbert Cortés-BullichÁlex BatallerClara MaluquerDolors ColomerMaría RozmanMontserrat ArnanBlanca Xicoy CiriciAleksandra HolowieckaMarina Díaz-Beyá
Published in: British journal of haematology (2023)
Recently modified diagnostic criteria for chronic myelomonocytic leukaemia (CMML) have lowered the cut-off for absolute monocytosis. In the largest series to date, we have analysed 313 CMML patients, including 104 with oligomonocytic (OM)-CMML. Five-year survival was longer for OM-CMML than for other patients (p < 0.001). Multivariate analysis identified OM-CMML as a favourable prognostic factor (HR 0.58; p = 0.002). The 5-year cumulative incidence of progression to classical CMML was 47%. Older age and transfusion dependence were adverse prognostic factors for OM-CMML. Our results support the inclusion of OM-CMML in the CMML category as a subtype with superior outcomes.
Keyphrases
  • prognostic factors
  • ejection fraction
  • newly diagnosed
  • type diabetes
  • emergency department
  • risk factors
  • adipose tissue
  • metabolic syndrome
  • weight loss
  • skeletal muscle
  • middle aged
  • patient reported
  • drug induced